Lithotripsy

Shockwave Medical to Report Second Quarter 2020 Financial Results on August 11, 2020

Retrieved on: 
Tuesday, July 21, 2020
Lithotripsy, Cardiovascular disease

SANTA CLARA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter 2020 after market close on Tuesday, August 11, 2020.

Key Points: 
  • SANTA CLARA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter 2020 after market close on Tuesday, August 11, 2020.
  • Company management will host a corresponding teleconference that will be webcasted live beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call may do so by dialing (866) 795-9106 for domestic callers or (470) 495-9173 for international callers, using conference ID: 8889064.
  • Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

Shockwave Appoints Maria Sainz to Board of Directors

Retrieved on: 
Monday, July 20, 2020
Medicine, Health sciences, Medical devices, Clinical medicine, Interventional cardiology, Lithotripsy, Coronary stent, Therapy, Stent, Batman The Escape

SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors and will serve on Shockwaves Compensation Committee.

Key Points: 
  • SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors and will serve on Shockwaves Compensation Committee.
  • I am delighted to welcome Maria to our Board of Directors, said Doug Godshall, President and Chief Executive Officer of Shockwave Medical.
  • Ms. Sainz has been intimately involved in the launches of several significant medical technology products including coronary stents and cardiac resynchronization therapy devices.
  • I am honored to join the Shockwave Medical Board of Directors, said Ms. Sainz.

Lumenis Launches Next-Generation MOSES™ 2.0 Holmium Laser Technology

Retrieved on: 
Wednesday, July 8, 2020
Medicine, Medical specialties, Clinical medicine, RTT, Laser medicine, Laser lithotripsy, Benign prostatic hyperplasia, Prostate cancer, Laser, Prostate, Holmium(III) oxide, Lithotripsy

Initially released in 2017, the MOSES technology is designed to greatly improve the efficiency of urinary stones and enlarged prostate (BPH) procedures by optimizing the laser energy transmission.

Key Points: 
  • Initially released in 2017, the MOSES technology is designed to greatly improve the efficiency of urinary stones and enlarged prostate (BPH) procedures by optimizing the laser energy transmission.
  • In BPH, MOSES 2.0 represents a major paradigm shift, transforming the clinically validated gold-standard therapy, Holmium Laser Enucleation of the Prostate (HoLEP), into an outpatient procedure with same day discharge, catheter-free.
  • Comparative Study of Holmium Laser Enucleation of the Prostate with MOSES Enabled Pulsed Laser Modulation.
  • Epub 2017 Dec 22
    Pulse Modulation Technology to Improve Holmium Laser Lithotripsy Outcomes: A preclinical study.

Lumenis Launches Next-Generation MOSES™ 2.0 Holmium Laser Technology

Retrieved on: 
Wednesday, July 8, 2020
Medicine, Medical specialties, Clinical medicine, RTT, Laser medicine, Laser lithotripsy, Benign prostatic hyperplasia, Prostate cancer, Laser, Prostate, Holmium(III) oxide, Lithotripsy

Initially released in 2017, the MOSES technology is designed to greatly improve the efficiency of urinary stones and enlarged prostate (BPH) procedures by optimizing the laser energy transmission.

Key Points: 
  • Initially released in 2017, the MOSES technology is designed to greatly improve the efficiency of urinary stones and enlarged prostate (BPH) procedures by optimizing the laser energy transmission.
  • In BPH, MOSES 2.0 represents a major paradigm shift, transforming the clinically validated gold-standard therapy, Holmium Laser Enucleation of the Prostate (HoLEP), into an outpatient procedure with same day discharge, catheter-free.
  • Comparative Study of Holmium Laser Enucleation of the Prostate with MOSES Enabled Pulsed Laser Modulation.
  • Epub 2017 Dec 22
    Pulse Modulation Technology to Improve Holmium Laser Lithotripsy Outcomes: A preclinical study.

Olympus Launches the Soltive SuperPulsed Thulium Fiber Laser System for Urology

Retrieved on: 
Wednesday, June 17, 2020
Optics, Medicine, Physical sciences, Laser medicine, Laser, Photonics, Thulium, Lithotripsy, Fiber laser, Laser lithotripsy, Laser surgery

CENTER VALLEY, Pa., June 17, 2020 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announces the commercial launch of the Soltive SuperPulsed Laser System (Soltive Laser System), a new application of thulium fiber laser technology designed for stone lithotripsy and soft tissue applications.

Key Points: 
  • CENTER VALLEY, Pa., June 17, 2020 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announces the commercial launch of the Soltive SuperPulsed Laser System (Soltive Laser System), a new application of thulium fiber laser technology designed for stone lithotripsy and soft tissue applications.
  • "The regulatory approval and launch of the Soltive Laser System introduce thulium fiber laser technology into the medical world globally.
  • In addition to the clinical improvements the new laser system makes over current systems, the Soltive Laser System offers ergonomic and environmental advantages.
  • With the improved dusting, cutting and hemostasis performance, the Soltive Laser System is a significant leap forward in laser technology that will assist urologists in achieving better outcomes," said Randy Clark, President of Olympus Medical Systems Group.

Olympus Launches the Soltive SuperPulsed Thulium Fiber Laser System for Urology

Retrieved on: 
Wednesday, June 17, 2020
Optics, Medicine, Physical sciences, Laser medicine, Laser, Photonics, Thulium, Lithotripsy, Fiber laser, Laser lithotripsy, Laser surgery

HAMBURG, Germany and TOKYO, June 17, 2020 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announces the commercial launch of the Soltive SuperPulsed Laser System (Soltive Laser System), a new application of thulium fiber laser technology designed for stone lithotripsy and soft tissue applications.

Key Points: 
  • HAMBURG, Germany and TOKYO, June 17, 2020 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announces the commercial launch of the Soltive SuperPulsed Laser System (Soltive Laser System), a new application of thulium fiber laser technology designed for stone lithotripsy and soft tissue applications.
  • "The regulatory approval and launch of the Soltive Laser System introduce thulium fiber laser technology into the medical world globally.
  • In addition to the clinical improvements the new laser system makes over current systems, the Soltive Laser System offers ergonomic and environmental advantages.
  • With the improved dusting, cutting and hemostasis performance, the Soltive Laser System is a significant leap forward in laser technology that will assist urologists in achieving better outcomes," said Randy Clark, President of Olympus Medical Systems Group.

EDAP TMS SA to Announce First Quarter 2020 Financial Results on May 13, 2020

Retrieved on: 
Wednesday, May 6, 2020
Medicine, Clinical medicine, Medical specialties, Medical ultrasonography, High-intensity focused ultrasound, Magnetic resonance imaging, Therapeutic ultrasound, Lithotripsy, Prostate cancer, Extracorporeal, Urology, Laser lithotripsy

A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology.

Key Points: 
  • A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology.
  • By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm Robotic HIFU and Ablatherm Fusion.
  • As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith range of ESWL systems.
  • For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

Shockwave Medical to Present at the Bank of America Securities 2020 Health Care Conference

Retrieved on: 
Thursday, April 30, 2020
Decepticons, Shockwave, Fictional characters, Lithotripsy, Fiction

SANTA CLARA, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced today that the company will be participating in the upcoming Bank of America Securities 2020 Health Care Conference that is being held virtually from May 12-14, 2020.

Key Points: 
  • SANTA CLARA, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced today that the company will be participating in the upcoming Bank of America Securities 2020 Health Care Conference that is being held virtually from May 12-14, 2020.
  • Shockwave Medicals management is scheduled for a live Fireside Chat on Thursday, May 14, 2019 at 10:20 a.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the event on the Investors section of the companys website at: https://ir.shockwavemedical.com .
  • Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

Shockwave Medical to Report First Quarter 2020 Financial Results on May 12, 2020

Retrieved on: 
Tuesday, April 21, 2020
Decepticons, Shockwave, Fictional characters, Lithotripsy, Fiction

SANTA CLARA, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the first quarter 2020 after market close on Tuesday, May 12, 2020.

Key Points: 
  • SANTA CLARA, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the first quarter 2020 after market close on Tuesday, May 12, 2020.
  • Company management will host a corresponding teleconference that will be webcasted live beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.
  • IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes.

EDAP TMS SA to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 30, 2020

Retrieved on: 
Tuesday, March 24, 2020
Medicine, Clinical medicine, Medical specialties, Medical ultrasonography, High-intensity focused ultrasound, Magnetic resonance imaging, Therapeutic ultrasound, Lithotripsy, Prostate cancer, Extracorporeal, Urology, Laser lithotripsy

A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology.

Key Points: 
  • A recognized leader in the global therapeutic ultrasound market for almost 40 years, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for urology using ultrasound technology.
  • By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One in 2013 in Europe and in 2018 in the US as the answer to all requirements for ideal prostate tissue ablation as a complement to the existing FDA-cleared Ablatherm Robotic HIFU and Ablatherm Fusion.
  • As a pioneer and key player in the field of extracorporeal shock wave lithotripsy (ESWL), EDAP TMS exclusively utilizes the latest generation of shock wave source in its Sonolith range of ESWL systems.
  • For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.